May 29, 2020

The Niche

Knoepfler lab stem cell blog

Astellas

1 min read

It’s been a busy few weeks for the stem cell field. Below are some news briefs on developments. RetractionWatch reports that Piero Anversa is leaving Harvard/Brigham and Women’s Hospital after an investigation and dismissed lawsuit he filed against the institution. All still quiet on the STAP cell front at the same institutions. There’s some more clarity and confusion over the Japanese regulatory sphere for IPS cells. New regs may not be issued for another 4 or more months, leaving the clinical studies there in …Read More

1 min read

Astellas Pharma is on track to purchase Ocata Therapeutics (formerly Advanced Cell Technology). This has stirred a lot of strong feelings amongst investors in Ocata. (Update, now almost 5 years later, the Ocata vision program is still not going full steam ahead at its new owner it seems). I’ve also been wondering what exactly is Astellas Pharma? Astellas is a giant compared to Ocata with reportedly $11 billion USD in revenue and $1.3 billion in profit just in the year 2013 alone. While Ocata …Read More